logo
Bird flu outbreaks in mammals double, raising human risk: report

Bird flu outbreaks in mammals double, raising human risk: report

Time of India24-05-2025
Paris: Outbreaks of bird flu in mammals more than doubled across the world last year, raising the risk that the virus could potentially spread between humans, an international agency warned on Friday.
Avian influenza has spread across the world like never before in the last few years, leading to the mass culling of poultry, sending egg prices soaring and causing the deaths of several people in contact with infected animals.
While the overall risk of human infection remains low, bird flu outbreaks among mammals such as cattle, dogs and cats increase the possibility that the virus could eventually adapt to transmit between humans, the
World Organisation for Animal Health
(WOAH) said in a new report.
The number of mammal outbreaks soared to 1,022 across 55 countries last year, compared to 459 in 2023, according to the Paris-based agency, which monitors animal diseases worldwide.
"It is concerning because it is a change in the pattern of the epidemiology of the virus," WOAH's director general Emmanuelle Soubeyran told AFP.
Health experts have been sounding the alarm about the potential pandemic threat posed by bird flu, which has shown signs of mutating as it spreads in particular among dairy cows in the United States.
The new report comes as the budgets of US health and science agencies have been slashed by the Trump administration.
This included the sacking earlier this year of the staff of an epidemiology programme known as the "disease detectives".
- 'Global emergency' -
Bird flu "is more than an animal health crisis -- it is a global emergency destabilising agriculture, food security, trade and ecosystems," the report warned.
More than 630 million birds have either died from avian influenza or been culled due to it over the last two decades, according to the agency's first annual State of the World's Animal Health report.
Wild birds have also suffered mass die-offs, although the exact number is difficult to estimate.
The report highlighted the role that vaccination can play in stemming outbreaks among birds -- which in turn decreases the risk to mammals and humans.
It cited the example of France, which started vaccinating poultry ducks against bird flu in 2023.
Modelling from the Toulouse Veterinary School estimated there would be 700 outbreaks in France that year. In the end, there were just 10, the report said.
Soubeyran said this was a "win-win" because it reduced exposure to humans -- and meant there were more poultry products available for export.
However, she emphasised that vaccines were not a "magic wand" and did not suit every situation.
Biosecurity, surveillance, increased transparency and global collaboration are also important tools to fight off the threat of bird flu, Soubeyran added, calling for more investment in these areas.
- Antibiotic use falls -
Last month Mexico reported its first human death from bird flu, a three-year-old girl.
The US recorded its first death in January, while there have been two deaths in Cambodia this year.
Nearly 50 percent of bird flu infections have historically proved fatal, according to the World Health Organization.
It says the human cases detected so far are mostly linked to people who had close contact with infected birds and other animals, or contaminated environments.
The WOAH report also warned more broadly about the rising danger of animal diseases crossing over into humans as climate change pushes species into new areas.
Nearly 70 percent of the emerging diseases notified to the agency over the last 20 years were considered to have the potential to pose a threat to human health, it said.
Another danger is the increasing resistance some diseases are having to antibiotics, which is "one of the greatest threats to global health, food security and economic stability", the report said.
In positive news, use of antibiotics in animals fell by five percent between 2020 and 2022.
Europe saw the biggest decline -- 23 percent, it added, calling for further reductions.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cheaper cancer care therapy earns big bucks for pharma company
Cheaper cancer care therapy earns big bucks for pharma company

Economic Times

time2 hours ago

  • Economic Times

Cheaper cancer care therapy earns big bucks for pharma company

India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.

Cheaper cancer care therapy earns big bucks for pharma company
Cheaper cancer care therapy earns big bucks for pharma company

Time of India

time3 hours ago

  • Time of India

Cheaper cancer care therapy earns big bucks for pharma company

ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.

Woman Denied Boarding At Miami Airport Due To Cosmetic Procedure, Airline Responds
Woman Denied Boarding At Miami Airport Due To Cosmetic Procedure, Airline Responds

NDTV

time3 hours ago

  • NDTV

Woman Denied Boarding At Miami Airport Due To Cosmetic Procedure, Airline Responds

A woman claimed that she was denied boarding by Spirit Airlines at Miami International Airport Wednesday afternoon because of concerns over a cosmetic procedure she underwent days earlier. The Houston-based woman, named Shataria Banks, captured a video of her confrontation at the Spirit Airlines desk at the airport. "Even though y'all have my medical clearance, even though my doctor's-y'all are still restricting me to fly," Banks is heard saying in the video. While speaking to CBS News, she said she had arrived in Miami from Houston last week for a cosmetic procedure. She didn't reveal details about the procedure and preferred to keep it private. She came to the airport with documentation from her doctor clearing her to fly after several days of recovery. However, she was told that she would not be allowed to board when she tried to check in. "Well, we don't have it in writing-verbatim-from their spirit supervisor. It was just how I was treated on top of them just neglecting what my doctor said," Banks said, describing the exchange with Spirit employees. Here's what the airline said: "The safety and well-being of our Guests is our top priority. Our records show the agents followed our procedures and consulted with a designated on-call medical professional via our vendor MedLink to verify the Guest's fitness to travel," Spirit Airlines said in a statement. "The medical professional at MedLink was informed of the Guest's documentation and advised that the Guest was not fit to travel based on their condition at the time and in the interest of their safety. The Guest was ultimately issued a refund for the flight." As per the report, Banks said that she understands the need for safety; however, she called for clearer protocols. "I'm not saying that they can't deny their travelers and they're looking out for their safety, but have something in place, because everybody don't have money to waste for a new flight. I never want to fly with them, ever, ever," she said. The airline paid her the refund.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store